Clinical Trials Logo

Solid Tumor clinical trials

View clinical trials related to Solid Tumor.

Filter by:

NCT ID: NCT06215846 Not yet recruiting - Solid Tumor Clinical Trials

A Clinical Study Evaluating the Safety and Efficacy of BioTTT001 in Patients With Malignant Solid Tumors

Start date: January 22, 2024
Phase: Phase 1
Study type: Interventional

This is a Phase 1 open-label study to evaluate the safety, tolerability, and pharmacokinetics of Recombinant Human nsIL12 Oncolytic Adenovirus Injection (BioTTT001) at dose of 5×10∧9VP、5×10∧10VP、5×10∧11VP in Patients With Malignant Solid Tumors. Subjects will be treated with a single dose of BioTTT001 Injection after the screening period.

NCT ID: NCT06212076 Not yet recruiting - Solid Tumor Clinical Trials

Phase I/II Study of IPG1094 in Advanced Solid Tumors Patients

Start date: February 20, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase 1, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD) characteristics and initial anti-tumor activity of IPG1094 in patients with advanced solid tumors. The study will be conducted in two parts: dose escalation phase (Part A) and expansion phase (Part B).

NCT ID: NCT06198426 Not yet recruiting - Solid Tumor Clinical Trials

A Study of IBI3004 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors

Start date: May 1, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This is an open-label, multicenter, dose escalation and expansion phase I /II study of IBI3004 in subjects with unresectable, locally advanced or metastatic solid tumors. It includes a phase 1 dose escalation and expansion section to identify Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) of IBI3004. Accelerated titration and the Bayesian Optimal Interval (BOIN) design is used to find the MTD or RP2D, and the maximum sample size is 46. One or more dose levels will be selected for dose expansion, each dose group will be expanded to 30 subjects.

NCT ID: NCT06190886 Not yet recruiting - Solid Tumor Clinical Trials

A First-in-human (FIH), Multicenter, Open-Label, Phase I Study of PTX-912 in Patients With Locally Advanced/Metastatic Solid Tumors

Start date: April 27, 2024
Phase: Phase 1
Study type: Interventional

The goal of this clinical trial is to evaluate the safety and tolerability of escalating doses of PTX-912 in patients with locally advanced or metastatic solid tumors. To evaluate the PK and immunogenicity profile of PTX-912. To evaluate the preliminary anti-tumor activity of PTX-912. Participants will be treated with PTX-912 via iv infusion, every 2 weeks until progression of disease, unacceptable toxicity, or 12 months of total study therapy.

NCT ID: NCT06150885 Not yet recruiting - Solid Tumor Clinical Trials

A Safety And Efficacy Study Of Allogeneic CAR Gamma-Delta T Cells in Subjects With Relapsed/Refractory Solid Tumors

CAR001
Start date: April 30, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This study is composed of phase I and IIa parts. The dose-escalation phase I part aims to find the maximum tolerated dose (MTD) and to identify the safety of CAR001 in subjects with relapsed/refractory solid tumor; the dose-expansion phase IIa part aims to evaluate the potential efficacy of CAR001 in subjects with relapsed/refractory non-small cell lung cancer (NSCLC), triple negative breast cancer (TNBC), colorectal cancer (CRC) or Glioblastoma multiforme (GBM).

NCT ID: NCT06134960 Not yet recruiting - Pancreatic Cancer Clinical Trials

NKG2D/CLDN18.21 CAR-T(KD-496) in the Treatment of Advanced NKG2DL+/CLDN18.2+ Solid Tumor

Start date: November 16, 2023
Phase: Phase 1
Study type: Interventional

This is a Phase 1, single-arm, single-center, open-label study to evaluate the safety and effectiveness of NKG2D/CLDN18.2-based CAR-T cells infusion in the treatment of advanced NKG2DL+/CLDN18.2+ solid tumors.

NCT ID: NCT06112041 Not yet recruiting - Solid Tumor Clinical Trials

The Prospective Clinical Study of Precision PRaG Therapy in Elderly Patients With Advanced Solid Malignant Tumors (PRaG9.0)

Start date: October 25, 2023
Phase: Phase 2
Study type: Interventional

This is an open-label, single-arm, Phase II investigator-initiated trial of hypofractionated radiotherapy combined with PD-L1 inhibitor sequential GM-CSF and thymopentin for treatment of elderly patients with advanced solid tumors, when the HER-2 positive patients are treated with extra antibody-drug conjugate.

NCT ID: NCT06046742 Not yet recruiting - Solid Tumor Clinical Trials

A Study of Intravenous M1-c6v1 for Locally Advanced or Metastatic Solid Tumors

Start date: May 10, 2024
Phase: Phase 1
Study type: Interventional

A Phase I Study of the Safety and Tolerability of M1-c6v1 Administered Via Intravenously for Treatment of Patients With Locally Advanced or Metastatic Solid Tumors

NCT ID: NCT06041035 Not yet recruiting - Solid Tumor Clinical Trials

A Study of QLS31905 Combination Chemotherapy as First-Line Treatment in Patients With Advanced Solid Tumors

Start date: October 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This study aims to evaluate the efficacy and safety of QLS31905 plus chemotherapy in patients with Claudin18.2-positive advanced solid tumors.

NCT ID: NCT06010342 Not yet recruiting - Solid Tumor Clinical Trials

A Study to Evaluate the Efficacy and Safety of TL118 in Solid Tumors Patients

Start date: May 2024
Phase: Phase 2
Study type: Interventional

The main objective of the study will be to evaluate the efficacy of TL118 in participants with solid tumors harboring NTRK gene fusions